RT Journal Article
T1 Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients.
A1 Gutiérrez-Gutiérrez, B
A1 Rodríguez-Baño, J
K1 Bloodstream infections
K1 Carbapenems
K1 Extended-spectrum beta-lactamases
K1 Mortality
K1 Treatment
K1 Urinary tract Infections
AB Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are a frequent cause of invasive infections worldwide. Carbapenems are nowadays the most used drugs to treat these infections. However, due to the increasing rates of resistance to these antimicrobials, carbapenem-sparing alternatives are being investigated. The aim of this narrative literature review is to summarize the published information on the currently available antibiotics for the treatment of ESBL-E infections, providing specific information on three subgroups of patients: Group 1, patients with severe infections or infections from high-risk sources or in severely immunocompromised patients; Group 2, patients with non-severe infections from intermediate-risk source; and Group 3, patients with non-severe urinary tract infection. For patients in Group 1, the current data would support the use of carbapenems. For milder infections, however, particularly urinary tract infections, other non-carbapenem antibiotics can be considered in selected cases, including beta-lactam/beta-lactam inhibitor combinations, cephamycins, temocillin and aminoglycosides. While specific studies should be performed in these situations, individualized decisions may be taken in order to avoid overuse of carbapenems.
YR 2019
FD 2019-04-12
LK http://hdl.handle.net/10668/13828
UL http://hdl.handle.net/10668/13828
LA en
DS RISalud
RD Apr 7, 2025